Weight-loss jabs for obese children are effective and help prevent battles around mealtimes, researchers have claimed.
Experts presented the findings at the European Congress on Obesity in Malaga, Spain.
They found that the drugs helped obese youngsters lose weight on top of a diet and lifestyle plan.
Weight-loss jabs, also known as GLP-1 receptor agonists, work by reducing food cravings.
They are available on the NHS for adults with a high body mass index (BMI) or through private providers.
The National Institute for Health and Care Excellence (Nice) stopped its appraisal of semaglutide (Wegovy) for use in 12 to 17-year-olds after the manufacturer, Novo Nordisk, said it was unable to provide evidence for submission.
In certain instances where there is a proven clinical need, specialist paediatric clinics can prescribe weight-loss injections.
Weight loss jabs could almost halve risk of obesity-related cancers beyond slimming down, study suggests
NHS trust accused of ‘covering up’ concerns about suspended surgeon should be criminally investigated, say families of patients
‘This thing has hijacked my mind’: Woman reveals devastating impact of little-known disorder
Dr Annika Janson, from Karolinska University Hospital in Sweden, presented the new research.
She said: “GLP-1 drugs are increasingly used to treat obesity in adults.
“They can also be used in children from the age of 12 and clinical trials have shown children lose 5-16% of their body weight after a year of treatment.”
Alongside this, Dr Janson said the jabs had results “beyond obesity”.
“The families reported reduced conflicts around food and improved capacity for other lifestyle adaptations,” she said.
She added: “It was easier to stick to meals and limit snacks. Portions could be downsized. For some children, not being hungry all the time is a new feeling.”
Side effects of weight-loss drugs include nausea, diarrhoea, stomach cramps and vision problems.
Follow our channel and never miss an update
A spokesperson for Novo Nordisk said the company hadn’t submitted evidence for Nice appraisal because it lacked “utility data and risk equations in linking weight loss in adolescents to long-term outcomes.”
It added that, at this time, it had no intention of making an evidence submission.
Last year, a report by the Food Foundation said that children in the UK were getting shorter, fatter and sicker due to “shocking levels” of poverty and food deprivation.
It found that obesity among 10 to 11-year-olds had increased by 30% since 2006, with one in five children classed as obese by the time they leave primary school.
It comes as new data presented by Novo Nordisk showed that Wegovy for adults could help protect against heart disease in the earliest stages.
Read more from Sky News:
‘Simple’ test can spot heart disease risk 10 years early – study
Lines suspended as power cut hits Tube
Trailblazing female jockey retires
Be the first to get Breaking News
Install the Sky News app for free
Alongside this, it was said to cut the risk of heart attack, stroke or early death in high-risk patients.
